Your browser doesn't support javascript.
loading
National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016.
Boutanos, C; Capdepont, M; Svrcek, M; Thélu, F; Guedj, N; Poizat, F; Bibeau, F; Turlin, B; Rousseau, A; Bardier, A; Selves, J; Desrousseaux, M; Le Pessot, F; Bonhomme, B; Laverrière, M-H; Julié, C; Eyremandi, R-P; Stanislas, S; Bazille, C; Daubech, A; Lazure, T; Bordier, M-S; Demoures, A; Rullier, Anne.
Affiliation
  • Boutanos C; Department of Pathology, CHU Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux cedex, France.
  • Capdepont M; Department of Pathology, CHU Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux cedex, France.
  • Svrcek M; Department of Pathology, CHU Saint-Antoine APHP, 184 Rue du Faubourg Saint-Antoine, 75012, Paris, France.
  • Thélu F; Pathologie Nord Unilabs, 60 Boulevard Jean-Baptiste Lebas, 59000, Lille, France.
  • Guedj N; Department of Pathology, CHU Beaujon APHP, 100 Boulevard du Général Leclerc, 92110, Clichy, France.
  • Poizat F; Department of Pathology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.
  • Bibeau F; Department of Pathology, Institut du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
  • Turlin B; Department of Pathology, CHU Rennes, 2 Rue Henri le Guilloux, 35000, Rennes, France.
  • Rousseau A; Biopath Aquitaine, 4 Allée des Musardises, 33185, Le Haillan, France.
  • Bardier A; Department of Pathology, CHU de La Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
  • Selves J; Department of Pathology, IUCT Oncopole, 1 Avenue Irène Joliot-Curie, 31100, Toulouse, France.
  • Desrousseaux M; Atlantic Pathologie, 24 avenue du Général Ducasse, 64100, Bayonne, France.
  • Le Pessot F; Service de Pathologie, CHU Rouen, 1 Rue de Germont, 76000, Rouen, France.
  • Bonhomme B; Department of Pathology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.
  • Laverrière MH; Department of Pathology, CHU Grenoble, BP 217, 38043, Grenoble, France.
  • Julié C; Department of Pathology, CHU Ambroise Paré APHP, 9 Avenue Charles de Gaulle, 92100, Boulogne-Billancourt, France.
  • Eyremandi RP; Laboratoire d'Anatomie et de Cytologie Pathologiques, 43 Avenue Gaston Phoebus, 64000, Pau, France.
  • Stanislas S; Department of Pathology, CH Pau, 4 Boulevard Hauterive, 64000, Pau, France.
  • Bazille C; Department of Pathology, CHU Caen, Avenue de la Côte de Nacre, 14033, Caen, France.
  • Daubech A; Cabinet de Pathologie, 259 Boulevard Godard, 33110, Le Bouscat, France.
  • Lazure T; Department of Pathology, CHU Kremlin-Bicêtre, 78 Rue du Général Leclerc, 94270, Le Kremlin-Bicêtre, France.
  • Bordier MS; Department of Pathology, CH Libourne, 112 Rue de la Marne, 33500, Libourne, France.
  • Demoures A; Department of Pathology, CH Périgueux, 80 Avenue Georges Pompidou, 24000, Périgueux, France.
  • Rullier A; Department of Pathology, CHU Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux cedex, France. anne.rullier@chu-bordeaux.fr.
Virchows Arch ; 474(5): 561-568, 2019 May.
Article in En | MEDLINE | ID: mdl-30729335
ABSTRACT
The quality of pathologic assessment of rectal cancer specimens is crucial for treatment efficiency and survival. The Royal College of Pathologists (RCP) recommends evaluating the quality of the pathology report in routine practice using three quality indicators (QIs) the number of lymph nodes (LNs) analyzed (≥ 12), the rate of venous invasion (VI ≥ 30%), and peritoneal involvement (pT4a ≥ 10%). In this study, we evaluated the three QIs of the French national pathology reports and compared them with British guidelines and assessed the influence of neoadjuvant radiochemotherapy on QIs. From January 1 to December 31, 2016, all pathology reports for rectal adenocarcinoma were collected from French departments. Neoadjuvant radiochemotherapy included long-course radiotherapy with concomitant 5-FU-based chemotherapy. A total of 983 rectal cancer pathology reports were evaluated. A median of 15 LNs were analyzed and 81% of centers had ≥ 12 LNs. The rate of VI was 30% and 41% of centers had ≥ 30% VI. The rate of pT4a was 4% and 18% of centers reported ≥ 10% pT4a. None of the centers reached the threshold for the three QIs. All three QIs were lower after radiochemotherapy compared to surgery alone. In conclusion, in French routine practice, the values of two of the three QIs (LNs analyzed and VI) were globally in line with RCP guidelines. However, the rate of pT4a was very low, particularly after radiochemotherapy, suggesting its low value in rectal cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rectal Neoplasms / Lymph Nodes / Lymphatic Metastasis Type of study: Clinical_trials / Guideline Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Virchows Arch Journal subject: BIOLOGIA MOLECULAR / PATOLOGIA Year: 2019 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rectal Neoplasms / Lymph Nodes / Lymphatic Metastasis Type of study: Clinical_trials / Guideline Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Virchows Arch Journal subject: BIOLOGIA MOLECULAR / PATOLOGIA Year: 2019 Document type: Article Affiliation country: France
...